Pfizer Shifts Focus from Acquisitions to AI in the Next Two Years
Pfizer has indicated it will not pursue major acquisitions for the next couple of years and instead focus on integrating artificial intelligence (AI) into its operations. This strategic shift aims to enhance efficiency, accelerate drug development, and improve financial performance.
Tickers: $PFE
Topics: Acquisitions Artificial Intelligence (AI) Company Strategy Pharmaceuticals